Citius Pharmaceuticals, Inc. Receives a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for LYMPHIR (Denileukin Diftitox) for the Treatment of Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma Yahoo Finance
Citius Pharmaceuticals, Inc. Receives a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for LYMPHIR (Denileukin Diftitox) for the Treatment of Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma Yahoo Finance
Five Sydney researchers announced as 2023 Young Tall Poppy ... University of Sydney
See the rest here: Ayala Pharmaceuticals Announces Abstracts on AL102 and AL101 Accepted for Presentation at ESMO Congress 2023
More: Recce Pharmaceuticals Completes First Cohort Dosing of Phase l/ll UTI Rapid Infusion Clinical Trial at Scientia Clinical Research
More here: Aspargo Laboratories, Inc. Announces Filing of Its Investigational New Drug Application for Sildenafil Oral Spray
See the rest here: CytomX Therapeutics to Report Second Quarter 2023 Financial Results on August 8, 2023
Continued here: APNIMED to Participate in the 43rd Annual Canaccord Genuity Global Growth Conference
Originally posted here: Zenas BioPharma Announces Publication of Phase 2 Study of Obexelimab, an Investigational Treatment for IgG4-Related Disease (IgG4-RD), in The Lancet...
View original post here: Ambrx Appoints Renu Vaish, M.Sc., as Chief Regulatory Officer to Lead Regulatory Affairs
See original here: Intelligent Bio Solutions Secures 8 New Customers with a Combined Workforce of Over 10,000 Employees Two Months into Product Launch in Australia
Recent Comments